Smith ARC, Davis SH, Murugesan D, Buchanan KI, Turner PA, Huggett M, Zuccotto F,
Rebollo-Lopez MJ, Lafuente-Monasterio MJ,
Sanz O, Santos Diaz G, Lelievre J, Ballell J,
Selenski C, Axtman M, Ghidelli-Disse S,
Pflaumer H, Bosche M, Drewes G, Freiberg
GM, Kurnick MD, Srikumaran M, Kempf DJ,
Green SR, Ray PC, Read K, Wyatt P, Barry CE,
Boshoff HI (2016) Essential but not vulnerable: indazole sulfonamides targeting inosine
monophosphate dehydrogenase as potential
leads against Mycobacterium tuberculosis. ACS
Infect Dis 3(1):18–33
24. Chen C, Gardete S, Jansen RS, Shetty A,
Dick T, Rhee KY, Dartois V (2018) Verapamil
targets membrane energetics in Mycobacterium
tuberculosis. Antimicrob Agents Chemother 62
(5):e02107–e02117
25. Ballinger E, Mosior J, Hartman T, BurnsHuang K, Gold B, Morris R, Goullieux L,
Blanc I, Vaubourgeix J, Lagrange S, Fraisse L,
Sans S, Couturier C, Bacque E, Rhee K, Scarry
SM, Aube J, Yang G, Ouerfelli O,
Schnappinger D, Ioerger TR, Engelhart CA,
McConnell JA, McAulay K, Fay A,
Roubert C, Sacchettini J, Nathan C (2019)
Opposing reactions in coenzyme A metabolism
sensitize Mycobacterium tuberculosis to enzyme
inhibition. Science 363(6426):eaau8959
26. Wang Z, Soni V, Marriner G, Kaneko T, Boshoff HIM, Barry CE, Rhee KY (2019) Mode-ofaction profiling reveals glutamine synthetase as
a collateral metabolic vulnerability of
M. tuberculosis to bedaquiline. Proc Natl Acad
Sci U S A 116(39):19646–19651
27. Villas-Boas SG, Mas S, Akesson M,
Smedsgaard J, Nielsen J (2005) Mass spectrometry in metabolome analysis. Mass Spectrom Rev 24(5):613–646
Metabolomics of Mycobacterium tuberculosis
593